Abstract: 【Abstract】 In recent years, biological agents have played an important role in the treatment of psoriasis, among which interleukin （IL）-23 inhibitors have shown favorable efficacy and safety. In addition, IL-23 inhibitors can influence the onset and development of psoriasis comorbidities, such as psoriatic arthritis, cardiovascular diseases, metabolic syndrome, and inflammatory bowel disease. This review first discusses the involvement of the IL-23/IL-17 pathway in the pathogenesis of various psoriasis comorbidities, and then summarizes the effects of IL-23 inhibitors on psoriasis comorbidities based on clinical trials, case reports, and Chinese and international guidelines, aiming to provide a reference for choosing appropriate treatments for psoriasis patients with different comorbidities.

Key words: Psoriasis, Comorbidity, Arthritis, psoriatic, Inflammatory bowel disease, Adverse cardiovascular events, Malignancy, Interleukin-23 inhibitors